Impact of umbilical cord mesenchymal stromal/stem cell secretome and cord blood serum in prostate cancer progression

• Autor(a) principal: Sousa, André
• Data de Publicação: 2023
• Outros Autores: Coelho, Pedro, Leite, Fernanda , Teixeira, Catarina , Rocha, Ana Catarina , Santos, Inês , Baylina, Pilar, Fernandes, Ruben , Soares, Raquel , Costa, Raquel , Gomes, Andreia
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.22/22718
• topic: Umbilical cord; Mesenchymal stem/stromal cells; Prostate cancer; Cord blood serum; Acellular therapy

Prostate cancer (PCa) is the second most common malignancy in men, and the ffth leading cause of death worldwide. Mesenchymal stromal/stem cells (MSC) have been identifed in PCa, although contradictory efects in malignant transformation and tumor progression have been described. Since umbilical cord (UC) MSC and cord blood serum (CBS) are rich in numerous growth and anti-infammatory factors, UC-MSC secretome and CBS are able to modulate tumor cell proliferation and survival as well as immunity and angiogenesis. In the present study, we address this relationship and investigate the infuence of UC-MSC secretome and CBS on two human PCa cell lines (PC3 and LNCaP) and a normal epithelial prostate cell line (HPEpiC). Our results disclosed that upon exposure to UC-MSC-conditioned medium or CBS, both PC3 and LNCaP cells exhibited reduced viability, proliferation, and motility while non-malignant epithelial prostate cells were unafected. These fndings were corroborated by expression analysis of AKT/PI3K signaling pathway, p53 and interleukin genes. UC-MSC and CBS factors decreased the expression of growth-stimulating AKT and PI3K efectors and simultaneously up-regulated the expression of tumor-suppressor p53. Moreover, a more anti-infammatory expression profle was found in both malignant PCa cell lines. Altogether, these results shed light into possible mechanisms by which UC-MSC and CBS reduce PCa progression, further reinforcing their potential use as novel therapeutic agents in PCa.